89bio to Participate in the 7th Annual Evercore HealthCONx Conference

GlobeNewswireNov 27 05:05

89Bio Inc. Reports Q3 2024 Financial Results

TipRanksNov 21 11:57

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024

GlobeNewswireNov 15 21:05

Express News | 89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024

BreakingsNov 15 21:05

89bio (ETNB) Receives a Hold From Oppenheimer

TipRanksNov 13 21:09

Reported Earlier, 89bio Prices Upsized $125M Public Offering Of 11,455,882 Common Stock At $8.50/Share And Pre-Funded Warrants

BenzingaNov 13 15:57